作者
David A. Palma,Houda Bahig,Andrew Hope,Stephen Harrow,Brock Debenham,Alexander V. Louie,Thi Trinh Thuc Vu,Édith Filion,Andrea Bezjak,Marie‐Pierre Campeau,Adele Duimering,Meredith Giuliani,Joanna Laba,Pencilla Lang,Benjamin H. Lok,Xiaotao Qu,Srinivas Raman,George Rodrigues,Christopher D. Goodman,Stewart Gaede,Julie Morisset,Andrew Warner,Inderdeep Dhaliwal,Christopher J. Ryerson
摘要
Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options.